The companies will market Angle's Parsortix system for harvesting circulating tumor cells with Qiagen's liquid biopsy product portfolio.
The firm said it intends to use net proceeds from the issuance of the notes for general corporate purposes.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The companies will use HTG EdgeSeq technology to develop NGS-based gene expression profiling assays to support a pharma company's therapeutic development.
A settlement would have prevented Qiagen from selling its GeneReader in the US, but the firm now offers an upgraded version of its chemistry.
Qiagen opened its Chinese translational medicine venture in 2013 in partnership with BioBay, a life sciences cluster in Suzhou Industrial Park.
The kit was previously approved by FDA for use on Qiagen's Rotor-Gene Q real-time PCR platform, which is one component of the automated QiaSymphony platform.
Qiagen will use NGS to develop gene expression profiles related to BMS immuno-oncology therapies; and the company has licensed IO therapy response biomarkers from JHU.
The company posted a 3 percent increase in molecular diagnostics sales at constant exchange rates, and a 3 percent decline in instrument sales.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.